Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 16/20 | 0.49 |
| ▸ | HTR6 | P50406 | 4/20 | 0.44 |
| ▸ | KDM6B | O15054 | 2/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM4B | O94953 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315263 | 1.00 | KDM4C (0.49) | KDM4CHTR6KDM6BKDM4AKDM4B | |
| SCHEMBL316505 | 0.82 | KDM4C (0.56) | KDM4CHTR6 | |
| SCHEMBL316488 | 0.81 | HTR6 (0.70) | HTR6 | |
| SCHEMBL316489 | 0.81 | HTR6 (0.70) | HTR6 | |
| SCHEMBL12510405 | 0.80 | KDM4C (0.49) | KDM4CHTR6 | |
| SCHEMBL315806 | 0.77 | KDM4C (0.59) | KDM4C | |
| SCHEMBL3986958 | 0.77 | KDM4C (0.59) | KDM4C | |
| SCHEMBL10110774 | 0.75 | KDM4C (0.53) | KDM4CHTR6 | |
| SCHEMBL12510404 | 0.75 | KDM4C (0.53) | KDM4CHTR6 | |
| SCHEMBL10110778 | 0.75 | KDM4C (0.62) | KDM4CHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9670151-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8889906-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2012-04-12 | — | — | US | disclosed |
| US-8093424-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-7981923-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7671235-B2 | N-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-N-methyl-methanesulfonamide; 5-HT6 and 5-HT2A receptor modulators; selectiveserotonin reuptake inhibitors; selective seotonin receptor antagonists;gastrointestinal disorders; irritable bowel syndrome; cental nervous system | ROCHE PALO ALTO LLC (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1831159-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2035370-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147771-A2 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1831159-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC | 2006-07-27 | — | — | US | disclosed |
| WO-2006066790-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015256-A1 | Tetralin and indane derivatives and uses thereof | INSRR, TTN, INSR | KDM4C 4729/4885HTR6 1360/4885KDM6B 4809/4885 |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | HTR2A, HTR1A, HTR5A | KDM4C 3019/4885HTR6 7/4885KDM6B 2328/4885 |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | CYP3A7, PARK7, IPO5 | KDM4C 4743/4885HTR6 939/4885KDM6B 4509/4885 |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | KDM4C 4754/4885HTR6 1638/4885KDM6B 4711/4885 |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | KDM4C 4754/4885HTR6 1638/4885KDM6B 4711/4885 |
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | KDM4C 4778/4885HTR6 829/4885KDM6B 4399/4885 |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | KDM4C 4778/4885HTR6 829/4885KDM6B 4399/4885 |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | KDM4C 4754/4885HTR6 1638/4885KDM6B 4711/4885 |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | KDM4C 4778/4885HTR6 829/4885KDM6B 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.